Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses

Nil A Schubert,Linda Schild,Stijn van Oirschot,Kaylee M Keller,Lindy K Alles,Lindy Vernooij,Marloes E Nulle,M Emmy M Dolman,Marlinde L van den Boogaard,Jan J Molenaar

European Journal of Cancer（2021）

引用 10|浏览38

暂无评分

摘要

•Idasanutlin and abemaciclib were the most potent MDM2i and CDK4/6i, respectively.•p53 and pRb pathway alterations do not correlate with MDM2i or CDK4/6i efficacy.•Idasanutlin and abemaciclib do not act synergistically in vitro nor in vivo in neuroblastoma.

查看译文

关键词

Neuroblastoma,Paediatric cancer,Precision medicine,MDM2,CDK4,CDKN2A,MDM2 inhibitor,Idasanutlin,CDK4/6 inhibitor,Abemaciclib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要